A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1800 participants.
Also called NCT03970031
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,800 participants
- Sponsor
- Cirius Therapeutics, Inc.
- Registry
-
NCT03970031
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03970031. Randomized; quadruple masking; primary purpose treatment. Start 2022-06 (anticipated); primary completion 2024-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
- Condition
- Type2 Diabetes
- Condition
- NASH - Nonalcoholic Steatohepatitis
- Condition
- Nonalcoholic Steatohepatitis
- Condition
- Non-Alcoholic Fatty Liver Disease
- Intervention (Drug)
- MSDC-0602K
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cirius Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03970031- Content hash
3f64f18d83758f5424fab222acce834448815efc1bfb9aae6a8f13d7e009daf5